Evidence map›Paper›PMID 40688520›Full record

ArticleJournal of Alzheimer's disease & Parkinsonism2023

A Blood Screening Test for Dementia with Lewy Bodies for Primary Care.

Melissa Petersen, Tanis J Ferman, Fan Zhang, Otto Pedraza, Zbigniew K Wszolek, Owen A Ross, Tori Como, David Julovich, Leigh A Johnson, James Hall and 2 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of Alzheimer's disease & Parkinsonism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Melissa PetersenDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Tanis J FermanDepartment of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida, USA.
Fan ZhangDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Otto PedrazaDepartment of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida, USA.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Owen A RossDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Tori ComoDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
David JulovichDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Leigh A JohnsonDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
James HallDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Sid E O'BryantDepartment of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.

Funding

THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI PENG, JUNMIN · 2019 to 2023
$14.5M
An Alzheimer's Blood Test for Primary CareR01AG058537 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E, YAFFE, KRISTINE · 2018 to 2020
$6.5M
NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG058537NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

Introduction: We sought to cross-validate our previously published blood test for detecting Dementia with Lewy Bodies (DLB). Method: Plasma samples were analyzed on 428 individuals (DLB n=89, Parkinson's Disease (PD) without dementia n=126, Alzheimer's Disease (AD) n=108, Normal Controls (NC) n=105). Results: The proteomic profile discriminated DLB and PD from NC with an AUC (Area Under the Curve) of 0.96 with demographics of age, sex and education. The proteomic profile also distinguished DLB from the PD group with an AUC of 0.92 with demographics. It further distinguished DLB, PD and AD from NC with an AUC of 0.95 as well as DLB from AD with an AUC of 0.92 with demographics. Discussion: This data provides additional evidence of the potential utility of a multi-tiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from NC, PD and AD that can be implemented in primary care settings to aid in the referral process.

Indexed as

Alzheimer’s diseaseBiomarker screeningBlood biomarkersDementia with lewy bodiesDetectionDiagnostic accuracyParkinson’s diseaseProteomics

Identifiers

PMID40688520
PMCPMC12276881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.